via Livemint.com
In a new study assessing the potential of a single-dose, intranasal COVID-19 vaccine, a team from the University of Iowa and the University of Georgia found that the vaccine fully protects mice against lethal COVID-19 infection. The vaccine also blocks animal-to-animal transmission of the virus.
The findings were published July 2 in the journal Science Advances.
“The currently available vaccines against COVID-19 are very successful, but the majority of the world’s population is still unvaccinated and there is a critical need for more vaccines that are easy to use and effective at stopping disease and transmission,” says Paul McCray, MD, professor of pediatrics-pulmonary medicine, and microbiology and immunology at the UI Carver College of Medicine, and co-leader of the study. “If this new COVID-19 vaccine proves effective in people, it may help block SARS-CoV-2 transmission and help control the COVID-19 pandemic.”
Unlike traditional vaccines that require an injection, this vaccine is administered through a nasal spray similar to those commonly used to vaccinate against influenza. The vaccine used in the study only requires a single dose and it may be stored at normal refrigerator temperatures for up to at least three months. Because it is given intranasally, the vaccine may also be easier to administer, especially for those who have a fear of needles.
“We have been developing this vaccine platform for more than 20 years, and we began working on new vaccine formulations to combat COVID-19 during the early days of the pandemic,” says Biao He, PhD, a professor in the University of Georgia’s Department of Infectious Diseases in the College of Veterinary Medicine and co-leader of the study. “Our preclinical data show that this vaccine not only protects against infection, but also significantly reduces the chances of transmission.”
The experimental vaccine uses a harmless parainfluenza virus 5 (PIV5) to deliver the SARS-CoV-2 spike protein into cells where it prompts an immune response that protects against COVID-19 infection. PIV5 is related to common cold viruses and easily infects different mammals, including humans, without causing significant disease. The research team has previously shown that this vaccine platform can completely protect experimental animals from another dangerous coronavirus disease called Middle Eastern Respiratory Syndrome (MERS).
The inhaled PIV5 vaccine developed by the team targets mucosal cells that line the nasal passages and airways. These cells are the main entry point for most SARS-CoV-2 infections and the site of early virus replication. Virus produced in these cells can invade deeper into the lungs and other organs in the body, which can lead to more severe disease. In addition, virus made in these cells can be easily shed through exhalation allowing transmission from one infected person to others.
Original Article: Inhaled COVID-19 vaccine prevents disease and transmission in animals
More from: University of Iowa | University of Georgia
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Inhalable Covid-19 vaccine
- LA County and Long Beach offer Novavax, the new COVID-19 vaccine
Doctors say Novavax, a new COVID-19 vaccine, is protein-based and doesn’t contain genetic material. Will folks who aren’t vaccinated go for the shot?
- NorthShore agrees to pay $10.3 million settlement in COVID-19 vaccine lawsuit over religious exemptions
As part of the settlement, NorthShore is agreeing to re-hire workers who were fired for refusing to get vaccinated for religious reasons.
- TwitchCon San Diego 2022 ditches COVID-19 restrictions and vaccine requirements
Masks are recommended not required, and you won't need to show a negative COVID-19 test or proof of vaccination to attend.
- What the future of COVID-19 vaccines might look like
When you imagine a single coronavirus, you probably picture ... Among them is the McMaster team, whose inhalable vaccine is also designed to target parts of the virus other than the spike protein.
- Inhalable Vaccine in development at NC State University
RALEIGH, N.C. (WTVD) -- An inhalable COVID-19 vaccine developed by North Carolina State University professor Ke Cheng and associates at UNC-Chapel Hill and Duke University demonstrated positive ...
Go deeper with Google Headlines on:
Inhalable Covid-19 vaccine
Go deeper with Bing News on:
Inhalable vaccines
- What the future of COVID-19 vaccines might look like
Here are some of the new vaccines that could eventually be rolling out. Doing away with syringes would be a win for the needle-phobic, but inhalable vaccines could also, some researchers hope ...
- Inhalable Vaccine in development at NC State University
RALEIGH, N.C. (WTVD) -- An inhalable COVID-19 vaccine developed by North Carolina State University professor Ke Cheng and associates at UNC-Chapel Hill and Duke University demonstrated positive ...
- Fighting COVID: Triangle researchers create potential inhalable vaccine
RALEIGH – Researchers have created an inhalable COVID-19 vaccine that is shelf stable at room temperature for up to three months, targets the lungs specifically and effectively, and allows for ...
- Novel inhalable COVID-19 vaccine
The scientists developed an inhalable vaccine by combining SARS-CoV-2 RBD with lung spheroid cell-derived Exos (LSC-Exo) surface, i.e., RBD-Exo, to create a virus-like particle (VLP) that mimics ...
- Inhalable COVID-19 vaccine shows promise in rodent model
Here we report the design and preclinical testing of an inhalable virus-like-particle as a COVID-19 vaccine that, after lyophilization, is stable at room temperature for over three months.